drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00461 | DB00586 | 598 | 1,512 | [
"DDInter1254",
"DDInter537"
] | Nabumetone | Diclofenac | Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. While slightly reduced, possibly due to a de... | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Moderate | 1 | [
[
[
598,
24,
1512
]
],
[
[
598,
6,
7950
],
[
7950,
45,
1512
]
],
[
[
598,
10,
11577
],
[
11577,
49,
1512
]
],
[
[
598,
54,
19122
],
[
1912... | [
[
[
"Nabumetone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
]
],
[
[
"Nabumetone",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",... | Nabumetone (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Diclofenac (Compound)
Nabumetone (Compound) palliates rheumatoid arthritis (Disease) and rheumatoid arthritis (Disease) is palliated by Diclofenac (Compound)
Nabumetone (Compound) is included by Nonsteroidal Anti-inflammatory Compounds (Pharmacolog... |
DB00903 | DB00912 | 1,680 | 473 | [
"DDInter686",
"DDInter1581"
] | Etacrynic acid | Repaglinide | A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as ... | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Moderate | 1 | [
[
[
1680,
24,
473
]
],
[
[
1680,
6,
1829
],
[
1829,
45,
473
]
],
[
[
1680,
21,
28809
],
[
28809,
60,
473
]
],
[
[
1680,
63,
1512
],
[
1512... | [
[
[
"Etacrynic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
]
],
[
[
"Etacrynic acid",
"{u} (Compound) binds {v} (Gene)",
"ALB"
],
[
"ALB",
"{u} (Gene) is bound by {v} (Compound... | Etacrynic acid (Compound) binds ALB (Gene) and ALB (Gene) is bound by Repaglinide (Compound)
Etacrynic acid (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Repaglinide (Compound)
Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac ... |
DB00529 | DB00738 | 789 | 485 | [
"DDInter779",
"DDInter1420"
] | Foscarnet | Pentamidine | An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV. | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Major | 2 | [
[
[
789,
25,
485
]
],
[
[
789,
21,
29097
],
[
29097,
60,
485
]
],
[
[
789,
23,
112
],
[
112,
62,
485
]
],
[
[
789,
24,
971
],
[
971,
... | [
[
[
"Foscarnet",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pentamidine"
]
],
[
[
"Foscarnet",
"{u} (Compound) causes {v} (Side Effect)",
"Eye pain"
],
[
"Eye pain",
"{u} (Side Effect) is caused by {v} (Compoun... | Foscarnet (Compound) causes Eye pain (Side Effect) and Eye pain (Side Effect) is caused by Pentamidine (Compound)
Foscarnet may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pentamid... |
DB00046 | DB00808 | 1,179 | 1,605 | [
"DDInter940",
"DDInter916"
] | Insulin lispro | Indapamide | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promote... | The most significant modifiable risk factor for cardiovascular disease and the most prominent contributor to all-cause mortality is hypertension. Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts an estimated 25% of adults globally. Treatment for hypertension should include a n... | Moderate | 1 | [
[
[
1179,
24,
1605
]
],
[
[
1179,
24,
811
],
[
811,
1,
1605
]
],
[
[
1179,
24,
1669
],
[
1669,
62,
1605
]
],
[
[
1179,
24,
964
],
[
964,
... | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indapamide"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metolazone"
],
... | Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Metolazone and Metolazone (Compound) resembles Indapamide (Compound)
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Minocycline and Minocycline may cause a minor interaction tha... |
DB00860 | DB01320 | 891 | 651 | [
"DDInter1513",
"DDInter783"
] | Prednisolone | Fosphenytoin | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repe... | Moderate | 1 | [
[
[
891,
24,
651
]
],
[
[
891,
62,
307
],
[
307,
1,
651
]
],
[
[
891,
63,
362
],
[
362,
1,
651
]
],
[
[
891,
6,
8374
],
[
8374,
45,
... | [
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Prednisolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[... | Prednisolone may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil (Compound) resembles Fosphenytoin (Compound)
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Fosphenytoin (Compound... |
DB03904 | DB08931 | 1,574 | 947 | [
"DDInter1903",
"DDInter1600"
] | Urea | Riociguat | A compound formed in the liver from ammonia produced by the deamination of amino acids. It is the principal end product of protein catabolism and constitutes about one half of the total urinary solids. | Riociguat is a soluble guanylate cyclase (sGC) agonist approved in the USA, Europe and several other regions for patients with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for the treatment of patients with inoperable CTEPH (chronic thromboembolic pulmonary hypertension), or persistent/recurre... | Moderate | 1 | [
[
[
1574,
24,
947
]
],
[
[
1574,
24,
1344
],
[
1344,
24,
947
]
],
[
[
1574,
24,
1455
],
[
1455,
63,
947
]
],
[
[
1574,
24,
1344
],
[
1344,... | [
[
[
"Urea",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Riociguat"
]
],
[
[
"Urea",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
],
[
"Canag... | Urea may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Riociguat
Urea may cause a moderate interaction that could exacerbate diseases when taken with Nitrous acid and Nitrous aci... |
DB00688 | DB09481 | 955 | 460 | [
"DDInter1251",
"DDInter1113"
] | Mycophenolate mofetil | Magnesium carbonate | Mycophenolate mofetil, also known as MMF or CellCept, is a prodrug of mycophenolic acid, and classified as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). This drug is an immunosuppressant combined with drugs such as [Cyclosporine] and corticosteroids to prevent organ rejection after hepatic, ren... | Magnesium carbonate, also known as magnesite, is a common over the counter remedy for heartburn and upset stomach caused by overproduction of acid in the stomach [FDA Label]. | Moderate | 1 | [
[
[
955,
24,
460
]
],
[
[
955,
24,
1620
],
[
1620,
24,
460
]
],
[
[
955,
63,
964
],
[
964,
24,
460
]
],
[
[
955,
1,
1096
],
[
1096,
... | [
[
[
"Mycophenolate mofetil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Mycophenolate mofetil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Mycophenolate mofetil may cause a moderate interaction that could exacerbate diseases when taken with Tetracycline and Tetracycline may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate
Mycophenolate mofetil may cause a moderate interaction that could exacerbate diseases wh... |
DB01087 | DB01242 | 1,520 | 1,237 | [
"DDInter1520",
"DDInter410"
] | Primaquine | Clomipramine | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Ad... | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or aro... | Moderate | 1 | [
[
[
1520,
24,
1237
]
],
[
[
1520,
64,
684
],
[
684,
1,
1237
]
],
[
[
1520,
63,
1164
],
[
1164,
1,
1237
]
],
[
[
1520,
63,
401
],
[
401,
... | [
[
[
"Primaquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
]
],
[
[
"Primaquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thioridazine"
],
[
"Thiori... | Primaquine may lead to a major life threatening interaction when taken with Thioridazine and Thioridazine (Compound) resembles Clomipramine (Compound)
Primaquine may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and Trimipramine (Compound) resembles Clomipramine (Compound)
Pri... |
DB01267 | DB01278 | 519 | 1,021 | [
"DDInter1381",
"DDInter1506"
] | Paliperidone | Pramlintide | Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2... | Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes. | Moderate | 1 | [
[
[
519,
24,
1021
]
],
[
[
519,
63,
1507
],
[
1507,
24,
1021
]
],
[
[
519,
24,
1042
],
[
1042,
63,
1021
]
],
[
[
519,
25,
1154
],
[
1154,
... | [
[
[
"Paliperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Paliperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dicyclomine"
],
... | Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Dicyclomine and Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide... |
DB01390 | DB11703 | 1,117 | 405 | [
"DDInter1683",
"DDInter9"
] | Sodium bicarbonate | Acalabrutinib | Sodium bicarbonate is a white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions. | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Moderate | 1 | [
[
[
1117,
24,
405
]
],
[
[
1117,
24,
478
],
[
478,
24,
405
]
],
[
[
1117,
62,
1194
],
[
1194,
24,
405
]
],
[
[
1117,
63,
463
],
[
463,
... | [
[
[
"Sodium bicarbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Sodium bicarbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotini... | Sodium bicarbonate may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Sodium bicarbonate may cause a minor interaction that can limit clinical effects when taken with Raniti... |
DB00761 | DB01075 | 1,621 | 1,376 | [
"DDInter1497",
"DDInter569"
] | Potassium chloride | Diphenhydramine | A white crystal or crystalline powder used as an electrolyte replenisher, in the treatment of hypokalemia, in buffer solutions, and in fertilizers and explosives. The FDA withdrew its approval for the use of all solid oral dosage form drug products containing potassium chloride that supply 100 mg or more of potassium p... | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnoti... | Major | 2 | [
[
[
1621,
25,
1376
]
],
[
[
1621,
64,
128
],
[
128,
24,
1376
]
],
[
[
1621,
25,
832
],
[
832,
24,
1376
]
],
[
[
1621,
24,
97
],
[
97,
... | [
[
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Potassium chloride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexbrompheniramine"
],
[
... | Potassium chloride may lead to a major life threatening interaction when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Potassium chloride may lead to a major life threatening interaction when taken with Tripelennamine... |
DB00480 | DB06643 | 1,668 | 1,136 | [
"DDInter1035",
"DDInter500"
] | Lenalidomide | Denosumab | Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties. It is a 4-amino-glutamyl analogue of [thalidomide] and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms. However, lenali... | Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss.... | Moderate | 1 | [
[
[
1668,
24,
1136
]
],
[
[
1668,
25,
1316
],
[
1316,
63,
1136
]
],
[
[
1668,
63,
482
],
[
482,
24,
1136
]
],
[
[
1668,
25,
1377
],
[
1377... | [
[
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
]
],
[
[
"Lenalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Durvalumab"
],
[
"Durvalu... | Lenalidomide may lead to a major life threatening interaction when taken with Durvalumab and Durvalumab may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cau... |
DB00361 | DB00641 | 134 | 467 | [
"DDInter1939",
"DDInter1675"
] | Vinorelbine | Simvastatin | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-g... | Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of _Aspergillus terreus_. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endog... | Moderate | 1 | [
[
[
134,
24,
467
]
],
[
[
134,
6,
8374
],
[
8374,
45,
467
]
],
[
[
134,
18,
17561
],
[
17561,
46,
467
]
],
[
[
134,
7,
2969
],
[
2969,
... | [
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
]
],
[
[
"Vinorelbine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound... | Vinorelbine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Simvastatin (Compound)
Vinorelbine (Compound) downregulates ORAI3 (Gene) and ORAI3 (Gene) is upregulated by Simvastatin (Compound)
Vinorelbine (Compound) upregulates CDKN1A (Gene) and CDKN1A (Gene) is upregulated by Simvastatin (Compound)
Vinorelb... |
DB00912 | DB15093 | 473 | 1,654 | [
"DDInter1581",
"DDInter1698"
] | Repaglinide | Somapacitan | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan wa... | Moderate | 1 | [
[
[
473,
24,
1654
]
],
[
[
473,
63,
168
],
[
168,
23,
1654
]
],
[
[
473,
24,
433
],
[
433,
24,
1654
]
],
[
[
473,
63,
1512
],
[
1512,
... | [
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[... | Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Somapacitan
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin and Er... |
DB04932 | DB11703 | 1,564 | 405 | [
"DDInter491",
"DDInter9"
] | Defibrotide | Acalabrutinib | Defibrotide is the sodium salt of a mixture of single-stranded oligodeoxyribonucleotides derived from porcine mucosal DNA. It has been shown to have antithrombotic, anti-inflammatory and anti-ischemic properties (but without associated significant systemic anticoagulant effects). It is marketed under the brand names Da... | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Major | 2 | [
[
[
1564,
25,
405
]
],
[
[
1564,
63,
383
],
[
383,
24,
405
]
],
[
[
1564,
24,
643
],
[
643,
24,
405
]
],
[
[
1564,
24,
738
],
[
738,
... | [
[
[
"Defibrotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Defibrotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentosan polysulfate"
],
[
... | Defibrotide may cause a moderate interaction that could exacerbate diseases when taken with Pentosan polysulfate and Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Defibrotide may cause a moderate interaction that could exacerbate diseases when taken w... |
DB01229 | DB12500 | 973 | 283 | [
"DDInter1377",
"DDInter714"
] | Paclitaxel | Fedratinib | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
973,
24,
283
]
],
[
[
973,
24,
351
],
[
351,
23,
283
]
],
[
[
973,
63,
122
],
[
122,
23,
283
]
],
[
[
973,
24,
1339
],
[
1339,
6... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
... | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Verapamil and Verapamil... |
DB00427 | DB00601 | 1,233 | 453 | [
"DDInter1879",
"DDInter1073"
] | Triprolidine | Linezolid | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the init... | Moderate | 1 | [
[
[
1233,
24,
453
]
],
[
[
1233,
7,
3603
],
[
3603,
46,
453
]
],
[
[
1233,
18,
2023
],
[
2023,
57,
453
]
],
[
[
1233,
24,
272
],
[
272,
... | [
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linezolid"
]
],
[
[
"Triprolidine",
"{u} (Compound) upregulates {v} (Gene)",
"ZFP36"
],
[
"ZFP36",
"{u} (Gene) is upregulated by {v}... | Triprolidine (Compound) upregulates ZFP36 (Gene) and ZFP36 (Gene) is upregulated by Linezolid (Compound)
Triprolidine (Compound) downregulates RAP1GAP (Gene) and RAP1GAP (Gene) is downregulated by Linezolid (Compound)
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Chlorphen... |
DB00818 | DB09472 | 898 | 1,383 | [
"DDInter1538",
"DDInter1693"
] | Propofol | Sodium sulfate | Propofol is an intravenous anaesthetic agent used for induction and maintenance of general anaesthesia. IV administration of propfol is used to induce unconsciousness after which anaesthesia may be maintained using a combination of medications. Recovery from propofol-induced anaesthesia is generally rapid and associate... | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Moderate | 1 | [
[
[
898,
24,
1383
]
],
[
[
898,
24,
609
],
[
609,
24,
1383
]
],
[
[
898,
63,
521
],
[
521,
24,
1383
]
],
[
[
898,
24,
971
],
[
971,
... | [
[
[
"Propofol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Propofol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
... | Propofol may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Propofol may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and... |
DB00572 | DB11732 | 85 | 1,097 | [
"DDInter136",
"DDInter1027"
] | Atropine | Lasmiditan | Atropine is an alkaloid originally synthesized from Atropa belladonna. It is a racemic mixture of d-and l-hyoscyamine, of which only l-hyoscyamine is pharmacologically active.[A251670,L42835] Atropine is generally available as a sulfate salt and can be administered by intravenous, subcutaneous, intramuscular, intraosse... | Lasmiditan is an oral medication used in the termination of migraine headaches that was first approved for use in the United States in October 2019.[L9338,L9356] It was also approved by the European Commission on August 17, 2022. Traditionally, the triptan class of anti-migraine medications (e.g. [sumatriptan]) have se... | Moderate | 1 | [
[
[
85,
24,
1097
]
],
[
[
85,
63,
701
],
[
701,
24,
1097
]
],
[
[
85,
24,
662
],
[
662,
24,
1097
]
],
[
[
85,
35,
1442
],
[
1442,
24... | [
[
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lasmiditan"
]
],
[
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
... | Atropine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Atropine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbino... |
DB00367 | DB00731 | 566 | 1,144 | [
"DDInter1061",
"DDInter1269"
] | Levonorgestrel | Nateglinide | Levonorgestrel (LNG) is a synthetic progestogen similar to [Progesterone] used in contraception and hormone therapy.[A181988,T659] Also known as Plan B, it is used as a single agent in emergency contraception, and as a hormonal contraceptive released from an intrauterine device, commonly referred to as an IUD. Some of ... | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Moderate | 1 | [
[
[
566,
24,
1144
]
],
[
[
566,
6,
8374
],
[
8374,
45,
1144
]
],
[
[
566,
21,
28787
],
[
28787,
60,
1144
]
],
[
[
566,
63,
1051
],
[
1051,... | [
[
[
"Levonorgestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
]
],
[
[
"Levonorgestrel",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Co... | Levonorgestrel (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Nateglinide (Compound)
Levonorgestrel (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Nateglinide (Compound)
Levonorgestrel may cause a moderate interaction that could exacerbate diseases when taken with Ami... |
DB00159 | DB00261 | 940 | 702 | [
"DDInter903",
"DDInter93"
] | Icosapent | Anagrelide | Important polyunsaturated fatty acid found in fish oils. It serves as the precursor for the prostaglandin-3 and thromboxane-3 families. A diet rich in eicosapentaenoic acid lowers serum lipid concentration, reduces incidence of cardiovascular disorders, prevents platelet aggregation, and inhibits arachidonic acid conve... | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Moderate | 1 | [
[
[
940,
24,
702
]
],
[
[
940,
18,
10375
],
[
10375,
57,
702
]
],
[
[
940,
21,
28723
],
[
28723,
60,
702
]
],
[
[
940,
24,
848
],
[
848,
... | [
[
[
"Icosapent",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anagrelide"
]
],
[
[
"Icosapent",
"{u} (Compound) downregulates {v} (Gene)",
"RPS4Y1"
],
[
"RPS4Y1",
"{u} (Gene) is downregulated by {v... | Icosapent (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Anagrelide (Compound)
Icosapent (Compound) causes Malnutrition (Side Effect) and Malnutrition (Side Effect) is caused by Anagrelide (Compound)
Icosapent may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB04951 | DB08903 | 187 | 996 | [
"DDInter1477",
"DDInter170"
] | Pirfenidone | Bedaquiline | Pirfenidone is a synthetic pyridone drug. It is an antifibrotic agent with anti-inflammatory and antioxidant properties that is used to treat idiopathic pulmonary fibrosis (IPF), which is a chronic, progressive form of interstitial pneumonia. While its mechanism of action is not yet fully understood, pirfenidone is pro... | Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affe... | Moderate | 1 | [
[
[
187,
24,
996
]
],
[
[
187,
63,
593
],
[
593,
24,
996
]
],
[
[
187,
24,
1613
],
[
1613,
63,
996
]
],
[
[
187,
62,
168
],
[
168,
2... | [
[
[
"Pirfenidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
],
[
[
"Pirfenidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
],
[
... | Pirfenidone may cause a moderate interaction that could exacerbate diseases when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline
Pirfenidone may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1... |
DB00054 | DB01191 | 1,432 | 1,039 | [
"DDInter6",
"DDInter518"
] | Abciximab | Dexfenfluramine | Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (αv... | Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was with... | Moderate | 1 | [
[
[
1432,
24,
1039
]
],
[
[
1432,
25,
1046
],
[
1046,
63,
1039
]
],
[
[
1432,
24,
578
],
[
578,
63,
1039
]
],
[
[
1432,
24,
935
],
[
935,
... | [
[
[
"Abciximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexfenfluramine"
]
],
[
[
"Abciximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Caplacizumab"
],
[
"Capla... | Abciximab may lead to a major life threatening interaction when taken with Caplacizumab and Caplacizumab may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may... |
DB00067 | DB01166 | 317 | 477 | [
"DDInter1921",
"DDInter379"
] | Vasopressin | Cilostazol | Vasopressin (arginine-vasopressin or antidiuretic hormone) is a nonapeptide primarily produced in the hypothalamus that exhibits diverse physiological functions related to diuresis, hemodynamic modulation, and behaviour.[A110, A111, A112, A113, A228008] Vasopressin is very similar to oxytocin, differing in the third an... | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Moderate | 1 | [
[
[
317,
24,
477
]
],
[
[
317,
23,
112
],
[
112,
23,
477
]
],
[
[
317,
24,
820
],
[
820,
63,
477
]
],
[
[
317,
24,
888
],
[
888,
24,... | [
[
[
"Vasopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Vasopressin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[... | Vasopressin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cilostazol
Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and A... |
DB00782 | DB09488 | 1,123 | 103 | [
"DDInter1535",
"DDInter23"
] | Propantheline | Acrivastine | A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking. | Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever. As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension, edema,... | Moderate | 1 | [
[
[
1123,
24,
103
]
],
[
[
1123,
24,
1405
],
[
1405,
24,
103
]
],
[
[
1123,
63,
85
],
[
85,
24,
103
]
],
[
[
1123,
62,
551
],
[
551,
... | [
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
]
],
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclobenzaprine"
... | Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Cyclobenzaprine and Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine
Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Atro... |
DB00290 | DB14811 | 329 | 385 | [
"DDInter219",
"DDInter979"
] | Bleomycin | Isatuximab | A complex of related glycopeptide antibiotics from <i>Streptomyces verticillus</i> consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0). It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin. | Isatuximab (formerly SAR650984) is a humanized, IgG1-derived monoclonal antibody (mAb) produced from a Chinese hamster ovary (CHO) cell line.[L12099,A191799] Structurally, isatuximab is comprised of two identical immunoglobulin kappa light chains and two identical immunoglobulin gamma heavy chains. It is a cytolytic an... | Moderate | 1 | [
[
[
329,
24,
385
]
],
[
[
329,
24,
1362
],
[
1362,
24,
385
]
],
[
[
329,
63,
440
],
[
440,
24,
385
]
],
[
[
329,
25,
770
],
[
770,
2... | [
[
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isatuximab"
]
],
[
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
... | Bleomycin may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Isatuximab
Bleomycin may cause a moderate interaction that could exacerbate diseases when taken with Filgrastim and Filgrastim m... |
DB00782 | DB04946 | 1,123 | 924 | [
"DDInter1535",
"DDInter907"
] | Propantheline | Iloperidone | A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking. | Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. O... | Moderate | 1 | [
[
[
1123,
24,
924
]
],
[
[
1123,
63,
1664
],
[
1664,
1,
924
]
],
[
[
1123,
63,
1425
],
[
1425,
25,
924
]
],
[
[
1123,
24,
519
],
[
519,
... | [
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloperidone"
]
],
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
],
... | Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone (Compound) resembles Iloperidone (Compound)
Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Cisapride and Cisapride may lead to a major life threatening... |
DB00405 | DB00476 | 128 | 109 | [
"DDInter517",
"DDInter608"
] | Dexbrompheniramine | Duloxetine | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval... | Moderate | 1 | [
[
[
128,
24,
109
]
],
[
[
128,
24,
758
],
[
758,
1,
109
]
],
[
[
128,
63,
1302
],
[
1302,
1,
109
]
],
[
[
128,
24,
717
],
[
717,
63,... | [
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duloxetine"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluoxetine"... | Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Fluoxetine and Fluoxetine (Compound) resembles Duloxetine (Compound)
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Protriptyline and Protriptyline (Compound) resembles ... |
DB00029 | DB09075 | 25 | 498 | [
"DDInter99",
"DDInter621"
] | Anistreplase | Edoxaban | Human tissue plasminogen activator, purified, glycosylated, 527 residues purified from CHO cells. Eminase is a lyophilized (freeze-dried) formulation of anistreplase, the p-anisoyl derivative of the primary Lys-plasminogen-streptokinase activator complex (a complex of Lys-plasminogen and streptokinase). A p-anisoyl gro... | Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to r... | Major | 2 | [
[
[
25,
25,
498
]
],
[
[
25,
23,
944
],
[
944,
62,
498
]
],
[
[
25,
24,
1004
],
[
1004,
63,
498
]
],
[
[
25,
24,
41
],
[
41,
24,
... | [
[
[
"Anistreplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Edoxaban"
]
],
[
[
"Anistreplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile",... | Anistreplase may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Edoxaban
Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Phenyl salicylate and Phe... |
DB00738 | DB01278 | 485 | 1,021 | [
"DDInter1420",
"DDInter1506"
] | Pentamidine | Pramlintide | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes. | Moderate | 1 | [
[
[
485,
24,
1021
]
],
[
[
485,
64,
839
],
[
839,
24,
1021
]
],
[
[
485,
24,
1539
],
[
1539,
24,
1021
]
],
[
[
485,
24,
9
],
[
9,
63... | [
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Pentamidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Grepafloxacin"
],
[
"Grep... | Pentamidine may lead to a major life threatening interaction when taken with Grepafloxacin and Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Ofloxacin and Ofloxacin may... |
DB01235 | DB13074 | 1,191 | 877 | [
"DDInter1054",
"DDInter1110"
] | Levodopa | Macimorelin | Levodopa is a prodrug of dopamine that is administered to patients with Parkinson's due to its ability to cross the blood-brain barrier[Label]. Levodopa can be metabolised to dopamine on either side of the blood-brain barrier and so it is generally administered with a dopa decarboxylase inhibitor like carbidopa to prev... | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Moderate | 1 | [
[
[
1191,
24,
877
]
],
[
[
1191,
63,
112
],
[
112,
23,
877
]
],
[
[
1191,
63,
85
],
[
85,
24,
877
]
],
[
[
1191,
24,
820
],
[
820,
2... | [
[
[
"Levodopa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Levodopa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
... | Levodopa may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Levodopa may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropin... |
DB01259 | DB12001 | 392 | 564 | [
"DDInter1024",
"DDInter7"
] | Lapatinib | Abemaciclib | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the trea... | Moderate | 1 | [
[
[
392,
24,
564
]
],
[
[
392,
63,
536
],
[
536,
24,
564
]
],
[
[
392,
25,
868
],
[
868,
24,
564
]
],
[
[
392,
25,
982
],
[
982,
63,... | [
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abemaciclib"
]
],
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secobarbital"
],
[
... | Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital and Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib
Lapatinib may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may c... |
DB01259 | DB11110 | 392 | 603 | [
"DDInter1024",
"DDInter1115"
] | Lapatinib | Magnesium citrate | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the ... | Moderate | 1 | [
[
[
392,
24,
603
]
],
[
[
392,
64,
57
],
[
57,
24,
603
]
],
[
[
392,
63,
789
],
[
789,
24,
603
]
],
[
[
392,
24,
9
],
[
9,
24,
... | [
[
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Lapatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
],
[
... | Lapatinib may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Foscarnet and Fosca... |
DB00041 | DB00352 | 1,648 | 482 | [
"DDInter38",
"DDInter1814"
] | Aldesleukin | Tioguanine | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Moderate | 1 | [
[
[
1648,
24,
482
]
],
[
[
1648,
23,
945
],
[
945,
62,
482
]
],
[
[
1648,
24,
151
],
[
151,
63,
482
]
],
[
[
1648,
24,
66
],
[
66,
2... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
]
],
[
[
"Aldesleukin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sparfloxacin"
],
[
... | Aldesleukin may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin and Sparfloxacin may cause a minor interaction that can limit clinical effects when taken with Tioguanine
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A... |
DB01619 | DB04843 | 830 | 1,511 | [
"DDInter1441",
"DDInter1149"
] | Phenindamine | Mepenzolate | Phenindamine is an antihistamine. Phenindamine blocks the effects of the naturally occurring chemical histamine in your body. Antihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine ... | Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ga... | Moderate | 1 | [
[
[
830,
24,
1511
]
],
[
[
830,
64,
675
],
[
675,
24,
1511
]
],
[
[
830,
1,
537
],
[
537,
24,
1511
]
],
[
[
830,
63,
1192
],
[
1192,
... | [
[
[
"Phenindamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
],
[
[
"Phenindamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dextropropoxyphene"
],
[
... | Phenindamine may lead to a major life threatening interaction when taken with Dextropropoxyphene and Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Phenindamine (Compound) resembles Cyclizine (Compound) and Cyclizine may cause a moderate interaction that c... |
DB06335 | DB11921 | 761 | 1,019 | [
"DDInter1646",
"DDInter492"
] | Saxagliptin | Deflazacort | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Moderate | 1 | [
[
[
761,
24,
1019
]
],
[
[
761,
63,
1072
],
[
1072,
23,
1019
]
],
[
[
761,
24,
192
],
[
192,
24,
1019
]
],
[
[
761,
63,
959
],
[
959,
... | [
[
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoniazid"
],
[
... | Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Isoniazid and Isoniazid may cause a minor interaction that can limit clinical effects when taken with Deflazacort
Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Esterified estrogens a... |
DB00048 | DB11166 | 1,595 | 18 | [
"DDInter435",
"DDInter104"
] | Collagenase clostridium histolyticum | Antithrombin Alfa | Collagenase clostridium histolyticum is an enzyme produced by the bacterium Clostridium histolyticum. It is beneficial in the breakdown of collagen plaques for the treatment of Dupuytren's contracture and Peyronie's disease. The topical formulation is used for the debridement of necrotic tissue due to burns or chronic ... | Antithrombin Alfa is a recombinant antithrombin , an anticoagulant, that is used for the prevention of thromboembolic events in patients that have hereditary deficiency of antithrombin in high risk situations. | Moderate | 1 | [
[
[
1595,
24,
18
]
],
[
[
1595,
24,
714
],
[
714,
24,
18
]
],
[
[
1595,
24,
1409
],
[
1409,
25,
18
]
],
[
[
1595,
24,
1421
],
[
1421,
... | [
[
[
"Collagenase clostridium histolyticum",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Antithrombin Alfa"
]
],
[
[
"Collagenase clostridium histolyticum",
"{u} may cause a moderate interaction that could exacerbate diseas... | Collagenase clostridium histolyticum may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Antithrombin Alfa
Collagenase clostridium histolyticum may cause a moderate interaction that could ex... |
DB00041 | DB11859 | 1,648 | 418 | [
"DDInter38",
"DDInter230"
] | Aldesleukin | Brexanolone | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | As of March 2019, brexanolone - developed and made available commercially by Sage Therapeutics Inc. as the brand name product Zulresso - is the first drug to have ever been approved by the US FDA specifically for the treatment of postpartum depression (PPD) in adult females . Since PPD, like various other types of depr... | Moderate | 1 | [
[
[
1648,
24,
418
]
],
[
[
1648,
24,
820
],
[
820,
24,
418
]
],
[
[
1648,
25,
593
],
[
593,
24,
418
]
],
[
[
1648,
24,
820
],
[
820,
... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexanolone"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Brexanolone
Aldesleukin may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cau... |
DB01175 | DB01218 | 318 | 1,493 | [
"DDInter672",
"DDInter852"
] | Escitalopram | Halofantrine | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible ... | Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferen... | Major | 2 | [
[
[
318,
25,
1493
]
],
[
[
318,
6,
12523
],
[
12523,
45,
1493
]
],
[
[
318,
21,
28810
],
[
28810,
60,
1493
]
],
[
[
318,
62,
112
],
[
112,... | [
[
[
"Escitalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Halofantrine"
]
],
[
[
"Escitalopram",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"H... | Escitalopram (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Halofantrine (Compound)
Escitalopram (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by Halofantrine (Compound)
Escitalopram may cause a minor interaction that can limit clinical effects whe... |
DB06674 | DB09389 | 908 | 517 | [
"DDInter837",
"DDInter1315"
] | Golimumab | Norgestrel | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Norgestrel is synthetic steroidal progestin that is used in combination with ethinyl estradiol for oral contraception. Norgestrel is composed of a racemic mixture of two stereoisomers, dextronorgestrel and levonorgestrel. However, only the levorotary enantiomer ([levonorgestrel]) is biologically active. | Moderate | 1 | [
[
[
908,
24,
517
]
],
[
[
908,
63,
14
],
[
14,
23,
517
]
],
[
[
908,
64,
581
],
[
581,
24,
517
]
],
[
[
908,
25,
812
],
[
812,
24,
... | [
[
[
"Golimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norgestrel"
]
],
[
[
"Golimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
],
[
... | Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may cause a minor interaction that can limit clinical effects when taken with Norgestrel
Golimumab may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause ... |
DB00081 | DB04865 | 273 | 4 | [
"DDInter1838",
"DDInter1335"
] | Tositumomab | Omacetaxine mepesuccinate | Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine). | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Major | 2 | [
[
[
273,
25,
4
]
],
[
[
273,
24,
496
],
[
496,
63,
4
]
],
[
[
273,
24,
563
],
[
563,
24,
4
]
],
[
[
273,
63,
1184
],
[
1184,
24,
... | [
[
[
"Tositumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Tositumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
... | Tositumomab may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine and Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Tositumomab may cause a moderate interaction that could exacerbate diseases wh... |
DB00694 | DB01255 | 51 | 633 | [
"DDInter485",
"DDInter1078"
] | Daunorubicin | Lisdexamfetamine | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Lisdexamfetamine is a prodrug of [dextroamphetamine], a central nervous system stimulant known as d-amphetamine, covalently attached to the naturally occurring amino acid L-lysine. Lisdexamfetamine is the first chemically formulated prodrug stimulant and was first approved by the FDA in April 2008. It was also approved... | Moderate | 1 | [
[
[
51,
24,
633
]
],
[
[
51,
21,
28751
],
[
28751,
60,
633
]
],
[
[
51,
23,
112
],
[
112,
23,
633
]
],
[
[
51,
63,
1494
],
[
1494,
2... | [
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lisdexamfetamine"
]
],
[
[
"Daunorubicin",
"{u} (Compound) causes {v} (Side Effect)",
"Convulsion"
],
[
"Convulsion",
"{u} (Side Eff... | Daunorubicin (Compound) causes Convulsion (Side Effect) and Convulsion (Side Effect) is caused by Lisdexamfetamine (Compound)
Daunorubicin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when take... |
DB09068 | DB09280 | 1,427 | 1,604 | [
"DDInter1948",
"DDInter1101"
] | Vortioxetine | Lumacaftor | Vortioxetine is an antidepressant medication indicated for the treatment of major depressive disorder (MDD). It is classified as a serotonin modulator and stimulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin r... | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Con... | Moderate | 1 | [
[
[
1427,
24,
1604
]
],
[
[
1427,
63,
1061
],
[
1061,
24,
1604
]
],
[
[
1427,
64,
593
],
[
593,
24,
1604
]
],
[
[
1427,
63,
840
],
[
840,
... | [
[
[
"Vortioxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumacaftor"
]
],
[
[
"Vortioxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
... | Vortioxetine may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor
Vortioxetine may lead to a major life threatening interaction when taken with Bupropion and Bupropion may ... |
DB00197 | DB00333 | 1,324 | 576 | [
"DDInter1881",
"DDInter1166"
] | Troglitazone | Methadone | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Methadone is a potent synthetic analgesic that works as a full µ-opioid receptor (MOR) agonist and N-methyl-d-aspartate (NMDA) receptor antagonist. As a full MOR agonist, methadone mimics the natural effects of the body's opioids, endorphins, and enkephalins through the release of neurotransmitters involved in pain tra... | Moderate | 1 | [
[
[
1324,
24,
576
]
],
[
[
1324,
24,
194
],
[
194,
40,
576
]
],
[
[
1324,
24,
307
],
[
307,
1,
576
]
],
[
[
1324,
24,
1033
],
[
1033,
... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methadone"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darifenacin"
],
... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Darifenacin and Darifenacin (Compound) resembles Methadone (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil (Compound) resembles Methadone (Compound... |
DB00262 | DB10795 | 552 | 221 | [
"DDInter302",
"DDInter1486"
] | Carmustine | Poliovirus type 1 antigen (formaldehyde inactivated) | A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogen... | Poliovirus type 1 antigen is a suspension of poliovirus Type 1 (Mahoney) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus Type 1. The vaccine contains purified and inactivated poliovirus type 1 that were grown from a c... | Moderate | 1 | [
[
[
552,
24,
221
]
],
[
[
552,
64,
581
],
[
581,
24,
221
]
],
[
[
552,
63,
599
],
[
599,
24,
221
]
],
[
[
552,
24,
384
],
[
384,
24,... | [
[
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Carmustine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"... | Carmustine may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Carmustine may cause a moderate interaction that could exacerbate diseases when taken... |
DB06228 | DB09036 | 792 | 812 | [
"DDInter1609",
"DDInter1668"
] | Rivaroxaban | Siltuximab | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be t... | Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). I... | Moderate | 1 | [
[
[
792,
24,
812
]
],
[
[
792,
63,
1461
],
[
1461,
23,
812
]
],
[
[
792,
64,
362
],
[
362,
24,
812
]
],
[
[
792,
63,
33
],
[
33,
24,... | [
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Siltuximab"
]
],
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
... | Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Siltuximab
Rivaroxaban may lead to a major life threatening interaction when taken with Phenytoin and Phenytoin may cause a mo... |
DB00444 | DB08908 | 63 | 713 | [
"DDInter1765",
"DDInter564"
] | Teniposide | Dimethyl fumarate | Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells ... | Dimethyl fumarate is an agent indicated for the treatment of relapsing forms of multiple sclerosis.[A253942,L43752] The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MM... | Moderate | 1 | [
[
[
63,
24,
713
]
],
[
[
63,
24,
4
],
[
4,
24,
713
]
],
[
[
63,
24,
270
],
[
270,
63,
713
]
],
[
[
63,
63,
134
],
[
134,
24,
7... | [
[
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
]
],
[
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesucc... | Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate
Teniposide may cause a moderate interaction that could exacerbate diseases ... |
DB00176 | DB00662 | 529 | 717 | [
"DDInter770",
"DDInter1873"
] | Fluvoxamine | Trimethobenzamide | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against e... | Moderate | 1 | [
[
[
529,
24,
717
]
],
[
[
529,
25,
1425
],
[
1425,
40,
717
]
],
[
[
529,
21,
28762
],
[
28762,
60,
717
]
],
[
[
529,
24,
1594
],
[
1594,
... | [
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethobenzamide"
]
],
[
[
"Fluvoxamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisapride"
],
[
"Ci... | Fluvoxamine may lead to a major life threatening interaction when taken with Cisapride and Cisapride (Compound) resembles Trimethobenzamide (Compound)
Fluvoxamine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Trimethobenzamide (Compound)
Fluvoxamine may cause a moderate interaction th... |
DB00424 | DB00934 | 19 | 413 | [
"DDInter896",
"DDInter1124"
] | Hyoscyamine | Maprotiline | Hyoscyamine is a tropane alkaloid and the levo-isomer of [atropine]. It is commonly extracted from plants in the _Solanaceae_ or nightshade family. Research into the action of hyoscyamine in published literature dates back to 1826. Hyoscyamine is used for a wide variety of treatments and therapeutics due to its antimus... | Maprotiline is a tetracyclic antidepressant with similar pharmacological properties to tricyclic antidepressants (TCAs). Similar to TCAs, maprotiline inhibits neuronal norepinephrine reuptake, possesses some anticholinergic activity, and does not affect monoamine oxidase activity. It differs from TCAs in that it does n... | Moderate | 1 | [
[
[
19,
24,
413
]
],
[
[
19,
63,
1302
],
[
1302,
40,
413
]
],
[
[
19,
6,
7992
],
[
7992,
45,
413
]
],
[
[
19,
18,
4930
],
[
4930,
57... | [
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Maprotiline"
]
],
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Protriptyline"
],
... | Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Protriptyline and Protriptyline (Compound) resembles Maprotiline (Compound)
Hyoscyamine (Compound) binds CHRM1 (Gene) and CHRM1 (Gene) is bound by Maprotiline (Compound)
Hyoscyamine (Compound) downregulates DLD (Gene) and DLD (G... |
DB00041 | DB00599 | 1,648 | 682 | [
"DDInter38",
"DDInter1795"
] | Aldesleukin | Thiopental | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | A barbiturate that is administered intravenously for the induction of general anesthesia or for the production of complete anesthesia of short duration. It is also used for hypnosis and for the control of convulsive states. It has been used in neurosurgical patients to reduce increased intracranial pressure. It does no... | Moderate | 1 | [
[
[
1648,
24,
682
]
],
[
[
1648,
24,
1023
],
[
1023,
1,
682
]
],
[
[
1648,
24,
401
],
[
401,
62,
682
]
],
[
[
1648,
24,
516
],
[
516,
... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiopental"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentobarbital"
],
... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Pentobarbital and Pentobarbital (Compound) resembles Thiopental (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a minor interaction t... |
DB01105 | DB15035 | 222 | 503 | [
"DDInter1665",
"DDInter1959"
] | Sibutramine | Zanubrutinib | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long... | Moderate | 1 | [
[
[
222,
24,
503
]
],
[
[
222,
63,
1324
],
[
1324,
24,
503
]
],
[
[
222,
24,
98
],
[
98,
24,
503
]
],
[
[
222,
23,
1619
],
[
1619,
2... | [
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
... | Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and ... |
DB00900 | DB08826 | 45 | 1,292 | [
"DDInter544",
"DDInter489"
] | Didanosine | Deferiprone | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-termi... | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA ap... | Moderate | 1 | [
[
[
45,
24,
1292
]
],
[
[
45,
21,
28809
],
[
28809,
60,
1292
]
],
[
[
45,
24,
72
],
[
72,
24,
1292
]
],
[
[
45,
63,
482
],
[
482,
25... | [
[
[
"Didanosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deferiprone"
]
],
[
[
"Didanosine",
"{u} (Compound) causes {v} (Side Effect)",
"Diarrhoea"
],
[
"Diarrhoea",
"{u} (Side Effect) is cau... | Didanosine (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Deferiprone (Compound)
Didanosine may cause a moderate interaction that could exacerbate diseases when taken with Eltrombopag and Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Defe... |
DB00434 | DB01043 | 13 | 108 | [
"DDInter459",
"DDInter1146"
] | Cyproheptadine | Memantine | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). It is different from many other Alzheimer's Disease medications, as it works by a different mechanism than the cholinesterase enzyme inhibitors normally employed in ... | Moderate | 1 | [
[
[
13,
24,
108
]
],
[
[
13,
6,
2250
],
[
2250,
45,
108
]
],
[
[
13,
7,
13230
],
[
13230,
46,
108
]
],
[
[
13,
21,
28852
],
[
28852,
... | [
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Memantine"
]
],
[
[
"Cyproheptadine",
"{u} (Compound) binds {v} (Gene)",
"DRD2"
],
[
"DRD2",
"{u} (Gene) is bound by {v} (Compound... | Cyproheptadine (Compound) binds DRD2 (Gene) and DRD2 (Gene) is bound by Memantine (Compound)
Cyproheptadine (Compound) upregulates TIPARP (Gene) and TIPARP (Gene) is upregulated by Memantine (Compound)
Cyproheptadine (Compound) causes Leukopenia (Side Effect) and Leukopenia (Side Effect) is caused by Memantine (Compoun... |
DB00762 | DB12267 | 613 | 1,476 | [
"DDInter973",
"DDInter233"
] | Irinotecan | Brigatinib | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cel... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
613,
24,
1476
]
],
[
[
613,
24,
1612
],
[
1612,
23,
1476
]
],
[
[
613,
25,
1206
],
[
1206,
23,
1476
]
],
[
[
613,
24,
629
],
[
629,
... | [
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
[
... | Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Irinotecan may lead to a major life threatening interaction when taken with Gemfibrozil and Gemfibrozil may caus... |
DB01115 | DB09054 | 336 | 384 | [
"DDInter1291",
"DDInter905"
] | Nifedipine | Idelalisib | Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development,... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
336,
24,
384
]
],
[
[
336,
63,
58
],
[
58,
24,
384
]
],
[
[
336,
40,
409
],
[
409,
24,
384
]
],
[
[
336,
24,
761
],
[
761,
24,
... | [
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
],
[
... | Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Nifedipine (Compound) resembles Felodipine (Compound) and Felodipine may cause a moderate interaction that could e... |
DB00014 | DB00850 | 521 | 1,630 | [
"DDInter839",
"DDInter1432"
] | Goserelin | Perphenazine | Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medi... | An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. | Moderate | 1 | [
[
[
521,
24,
1630
]
],
[
[
521,
24,
252
],
[
252,
40,
1630
]
],
[
[
521,
25,
684
],
[
684,
40,
1630
]
],
[
[
521,
21,
29232
],
[
29232,
... | [
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perphenazine"
]
],
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyzine"
],
[
... | Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyzine and Hydroxyzine (Compound) resembles Perphenazine (Compound)
Goserelin may lead to a major life threatening interaction when taken with Thioridazine and Thioridazine (Compound) resembles Perphenazine (Compound)
Goserel... |
DB00631 | DB14731 | 372 | 1,518 | [
"DDInter405",
"DDInter1741"
] | Clofarabine | Tagraxofusp | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Tagraxofusp is a CD123-directed cytotoxin. It is a fusion protein composed of a human interleukin-3 (IL-3) that is genetically fused to the catalytic and translocation domains of truncated diphtheria toxin (DT) produced in _Escherichia coli_.[A253762, A253887, L43702] Tagraxofusp received its first global approval by t... | Moderate | 1 | [
[
[
372,
24,
1518
]
],
[
[
372,
63,
1324
],
[
1324,
24,
1518
]
],
[
[
372,
24,
1130
],
[
1130,
24,
1518
]
],
[
[
372,
24,
242
],
[
242,
... | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tagraxofusp"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
... | Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Tagraxofusp
Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone a... |
DB08864 | DB11978 | 786 | 124 | [
"DDInter1595",
"DDInter822"
] | Rilpivirine | Glasdegib | Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potenc... | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Moderate | 1 | [
[
[
786,
24,
124
]
],
[
[
786,
62,
112
],
[
112,
23,
124
]
],
[
[
786,
63,
79
],
[
79,
24,
124
]
],
[
[
786,
64,
752
],
[
752,
24,
... | [
[
[
"Rilpivirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Rilpivirine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Rilpivirine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Rilpivirine may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sora... |
DB00046 | DB01064 | 1,179 | 1,148 | [
"DDInter940",
"DDInter987"
] | Insulin lispro | Isoprenaline | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promote... | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | Moderate | 1 | [
[
[
1179,
24,
1148
]
],
[
[
1179,
24,
1636
],
[
1636,
24,
1148
]
],
[
[
1179,
24,
251
],
[
251,
23,
1148
]
],
[
[
1179,
24,
1220
],
[
1220... | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylephrine"
... | Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Phenylephrine and Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Betam... |
DB01619 | DB06204 | 830 | 768 | [
"DDInter1441",
"DDInter1746"
] | Phenindamine | Tapentadol | Phenindamine is an antihistamine. Phenindamine blocks the effects of the naturally occurring chemical histamine in your body. Antihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine ... | Tapentadol is a centrally-acting synthetic analgesic with a dual mechanism of action. It is a mu-opioid receptor agonist that also inhibits norepinephrine reuptake.[A260721, A36596] Tapentadol was first approved by the FDA on November 20, 2008. The extended-release formulation of tapentadol was also approved by the FDA... | Moderate | 1 | [
[
[
830,
24,
768
]
],
[
[
830,
63,
1123
],
[
1123,
24,
768
]
],
[
[
830,
40,
104
],
[
104,
24,
768
]
],
[
[
830,
24,
849
],
[
849,
6... | [
[
[
"Phenindamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tapentadol"
]
],
[
[
"Phenindamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propantheline"
],
... | Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Propantheline and Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Tapentadol
Phenindamine (Compound) resembles Methdilazine (Compound) and Methdilazine may cause a moderate interact... |
DB01254 | DB12010 | 1,213 | 214 | [
"DDInter484",
"DDInter785"
] | Dasatinib | Fostamatinib | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
1213,
24,
214
]
],
[
[
1213,
25,
976
],
[
976,
24,
214
]
],
[
[
1213,
63,
1428
],
[
1428,
24,
214
]
],
[
[
1213,
64,
690
],
[
690,
... | [
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitin... | Dasatinib may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Isradipine and Isradipine may caus... |
DB01155 | DB11248 | 872 | 1,193 | [
"DDInter813",
"DDInter1965"
] | Gemifloxacin | Zinc gluconate | Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase... | Zinc gluconate is a zinc salt of gluconic acid comprised of two gluconic acid molecules for each zinc cation (2+). Zinc gluconate is a generally recognized as safe (GRAS) substance by FDA . It is available as a trace mineral supplement and over the counter as a lozenge form for a reduced duration of common colds and wi... | Moderate | 1 | [
[
[
872,
24,
1193
]
],
[
[
872,
63,
1096
],
[
1096,
23,
1193
]
],
[
[
872,
24,
1596
],
[
1596,
23,
1193
]
],
[
[
872,
64,
167
],
[
167,
... | [
[
[
"Gemifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zinc gluconate"
]
],
[
[
"Gemifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
... | Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with I... |
DB00789 | DB01359 | 1,431 | 729 | [
"DDInter796",
"DDInter1417"
] | Gadopentetic acid | Penbutolol | A complex of gadolinium with a chelating agent, diethylenetriamine penta-acetic acid (DTPA see pentetic acid), that is given to enhance the image in cranial and spinal MRIs. (From Martindale, The Extra Pharmacopoeia, 30th ed, p706) | Penbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker. Penbutolol can act as a partial agonist at beta adrenergic receptors, since it is a sympathomimetric drug. Penbutolol also demonstrates high... | Moderate | 1 | [
[
[
1431,
24,
729
]
],
[
[
1431,
63,
461
],
[
461,
1,
729
]
],
[
[
1431,
24,
699
],
[
699,
40,
729
]
],
[
[
1431,
21,
28762
],
[
28762,
... | [
[
[
"Gadopentetic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Penbutolol"
]
],
[
[
"Gadopentetic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"
... | Gadopentetic acid may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol (Compound) resembles Penbutolol (Compound)
Gadopentetic acid may cause a moderate interaction that could exacerbate diseases when taken with Nadolol and Nadolol (Compound) resembles Penbutolol (Compound... |
DB01010 | DB08865 | 61 | 1,593 | [
"DDInter622",
"DDInter448"
] | Edrophonium | Crizotinib | A rapid-onset, short-acting cholinesterase inhibitor used in cardiac arrhythmias and in the diagnosis of myasthenia gravis. It has also been used as an antidote to curare principles. | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Moderate | 1 | [
[
[
61,
24,
1593
]
],
[
[
61,
21,
28658
],
[
28658,
60,
1593
]
],
[
[
61,
63,
479
],
[
479,
23,
1593
]
],
[
[
61,
63,
751
],
[
751,
... | [
[
[
"Edrophonium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Edrophonium",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caus... | Edrophonium (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Crizotinib (Compound)
Edrophonium may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Crizotinib
... |
DB00741 | DB13139 | 167 | 1,032 | [
"DDInter885",
"DDInter1063"
] | Hydrocortisone | Levosalbutamol | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Levosalbutamol, or levalbuterol, is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). [Salbutamol] has been marketed as a racemic mixture, although beta2-agonist activity resides almost exclusively in the (R)-enantiomer. The enantioselective ... | Minor | 0 | [
[
[
167,
23,
1032
]
],
[
[
167,
1,
1573
],
[
1573,
23,
1032
]
],
[
[
167,
40,
870
],
[
870,
23,
1032
]
],
[
[
167,
24,
1213
],
[
1213,
... | [
[
[
"Hydrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Levosalbutamol"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisone"
],
[
"Prednisone",
"{u} may cause... | Hydrocortisone (Compound) resembles Prednisone (Compound) and Prednisone may cause a minor interaction that can limit clinical effects when taken with Levosalbutamol
Hydrocortisone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a minor interaction that can limit clinical effects when take... |
DB01255 | DB06595 | 633 | 1,491 | [
"DDInter1078",
"DDInter1214"
] | Lisdexamfetamine | Midostaurin | Lisdexamfetamine is a prodrug of [dextroamphetamine], a central nervous system stimulant known as d-amphetamine, covalently attached to the naturally occurring amino acid L-lysine. Lisdexamfetamine is the first chemically formulated prodrug stimulant and was first approved by the FDA in April 2008. It was also approved... | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Moderate | 1 | [
[
[
633,
24,
1491
]
],
[
[
633,
62,
112
],
[
112,
23,
1491
]
],
[
[
633,
63,
888
],
[
888,
24,
1491
]
],
[
[
633,
24,
657
],
[
657,
... | [
[
[
"Lisdexamfetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Lisdexamfetamine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
... | Lisdexamfetamine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Lisdexamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Tamoxi... |
DB00757 | DB01001 | 1,166 | 688 | [
"DDInter581",
"DDInter1632"
] | Dolasetron | Salbutamol | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is no... | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Moderate | 1 | [
[
[
1166,
24,
688
]
],
[
[
1166,
24,
455
],
[
455,
24,
688
]
],
[
[
1166,
25,
1148
],
[
1148,
63,
688
]
],
[
[
1166,
6,
8374
],
[
8374,
... | [
[
[
"Dolasetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
]
],
[
[
"Dolasetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
[
... | Dolasetron may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol
Dolasetron may lead to a major life threatening interaction when taken with Isoprenaline and Isoprenaline may ca... |
DB01263 | DB06788 | 859 | 1,616 | [
"DDInter1494",
"DDInter864"
] | Posaconazole | Histrelin | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-con... | Moderate | 1 | [
[
[
859,
24,
1616
]
],
[
[
859,
62,
112
],
[
112,
23,
1616
]
],
[
[
859,
24,
1342
],
[
1342,
24,
1616
]
],
[
[
859,
63,
77
],
[
77,
... | [
[
[
"Posaconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
]
],
[
[
"Posaconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Posaconazole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Histrelin
Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin and R... |
DB00631 | DB01181 | 372 | 1,532 | [
"DDInter405",
"DDInter906"
] | Clofarabine | Ifosfamide | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Moderate | 1 | [
[
[
372,
24,
1532
]
],
[
[
372,
5,
11555
],
[
11555,
44,
1532
]
],
[
[
372,
21,
29209
],
[
29209,
60,
1532
]
],
[
[
372,
24,
1299
],
[
129... | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Clofarabine",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Dise... | Clofarabine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ifosfamide (Compound)
Clofarabine (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Ifosfamide (Compound)
Clofarabine may cause a moderate interaction that could exacerbate diseases w... |
DB00169 | DB01070 | 386 | 1,098 | [
"DDInter367",
"DDInter558"
] | Cholecalciferol | Dihydrotachysterol | Vitamin D, in general, is a secosteroid generated in the skin when 7-dehydrocholesterol located there interacts with ultraviolet irradiation - like that commonly found in sunlight. Both the endogenous form of vitamin D (that results from 7-dehydrocholesterol transformation), vitamin D3 (cholecalciferol), and the plant-... | A vitamin D that can be regarded as a reduction product of vitamin D2. | Major | 2 | [
[
[
386,
25,
1098
]
],
[
[
386,
40,
1113
],
[
1113,
1,
1098
]
],
[
[
386,
40,
11418
],
[
11418,
40,
1098
]
],
[
[
386,
75,
160
],
[
160,
... | [
[
[
"Cholecalciferol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dihydrotachysterol"
]
],
[
[
"Cholecalciferol",
"{u} (Compound) resembles {v} (Compound)",
"Calcitriol"
],
[
"Calcitriol",
"{u} (Compound) resem... | Cholecalciferol (Compound) resembles Calcitriol (Compound) and Calcitriol (Compound) resembles Dihydrotachysterol (Compound)
Cholecalciferol (Compound) resembles Alfacalcidol (Compound) and Alfacalcidol (Compound) resembles Dihydrotachysterol (Compound)
Cholecalciferol (Compound) resembles Calcifediol (Compound) and Ch... |
DB06282 | DB09117 | 516 | 957 | [
"DDInter1053",
"DDInter1391"
] | Levocetirizine | Paraldehyde | Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine. Levocetirizine was granted FDA approval in 1995. | Paraldehyde was initially introduced into medical practice in the United Kingdom in 1882 by the Italian physician Vincenzo Cervello. It is classified as a central nervous system (CNS) depressant and has also been found to be an effective anticonvulsant, hypnotic and sedative agent due to its CNS depressant properties. ... | Moderate | 1 | [
[
[
516,
24,
957
]
],
[
[
516,
63,
1264
],
[
1264,
24,
957
]
],
[
[
516,
24,
407
],
[
407,
63,
957
]
],
[
[
516,
24,
849
],
[
849,
2... | [
[
[
"Levocetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paraldehyde"
]
],
[
[
"Levocetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
... | Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Paraldehyde
Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium ma... |
DB00196 | DB00734 | 600 | 1,664 | [
"DDInter743",
"DDInter1605"
] | Fluconazole | Risperidone | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. ... | Moderate | 1 | [
[
[
600,
24,
1664
]
],
[
[
600,
25,
924
],
[
924,
40,
1664
]
],
[
[
600,
24,
519
],
[
519,
40,
1664
]
],
[
[
600,
6,
4973
],
[
4973,
... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
]
],
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iloperidone"
],
[
"Iloper... | Fluconazole may lead to a major life threatening interaction when taken with Iloperidone and Iloperidone (Compound) resembles Risperidone (Compound)
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone and Paliperidone (Compound) resembles Risperidone (Compound)
Fluco... |
DB00312 | DB00405 | 1,023 | 128 | [
"DDInter1423",
"DDInter517"
] | Pentobarbital | Dexbrompheniramine | A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Dr... | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | Moderate | 1 | [
[
[
1023,
24,
128
]
],
[
[
1023,
24,
662
],
[
662,
63,
128
]
],
[
[
1023,
1,
288
],
[
288,
24,
128
]
],
[
[
1023,
64,
475
],
[
475,
... | [
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
]
],
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine... | Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine
Pentobarbital (Compound) resembles Butalbital (Compound) and Butalbital may cause a moderate in... |
DB01229 | DB08912 | 973 | 1,040 | [
"DDInter1378",
"DDInter462"
] | Paclitaxel (protein-bound) | Dabrafenib | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
973,
24,
1040
]
],
[
[
973,
6,
13478
],
[
13478,
45,
1040
]
],
[
[
973,
18,
10351
],
[
10351,
46,
1040
]
],
[
[
973,
7,
3466
],
[
3466... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Paclitaxel",
"{u} (Compound) binds {v} (Gene)",
"SLCO1B3"
],
[
"SLCO1B3",
"{u} (Gene) is bound by {v} (Compound)... | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Paclitaxel (Compound) binds SLCO1B3 (Gene) and SLCO1B3 (Gene) is bound by Dabrafenib (Compound)
Paclitaxel (Compound) downregulates ATF6 (Gene) and ATF6 (Gene) is upregulated by Dabrafenib (Compound)
Paclitaxel (Compou... |
DB00957 | DB06273 | 873 | 980 | [
"DDInter1314",
"DDInter1824"
] | Norgestimate | Tocilizumab | Norgestimate was first described in the literature in 1977. It was developed by Ortho Pharmaceutical Corporation as part of an effort to develop new hormonal contraceptives with reduced adverse effects. It is commonly formulated with [ethinylestradiol] as a combined oral contraceptive that can also be used to treat mod... | Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 J... | Moderate | 1 | [
[
[
873,
24,
980
]
],
[
[
873,
40,
1336
],
[
1336,
24,
980
]
],
[
[
873,
63,
58
],
[
58,
24,
980
]
],
[
[
873,
23,
14
],
[
14,
24,
... | [
[
[
"Norgestimate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tocilizumab"
]
],
[
[
"Norgestimate",
"{u} (Compound) resembles {v} (Compound)",
"Etonogestrel"
],
[
"Etonogestrel",
"{u} may cause ... | Norgestimate (Compound) resembles Etonogestrel (Compound) and Etonogestrel may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Norgestimate may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction tha... |
DB00054 | DB00574 | 1,432 | 121 | [
"DDInter6",
"DDInter717"
] | Abciximab | Fenfluramine | Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (αv... | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients ty... | Moderate | 1 | [
[
[
1432,
24,
121
]
],
[
[
1432,
25,
366
],
[
366,
24,
121
]
],
[
[
1432,
24,
24
],
[
24,
24,
121
]
],
[
[
1432,
24,
958
],
[
958,
6... | [
[
[
"Abciximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenfluramine"
]
],
[
[
"Abciximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eptifibatide"
],
[
"Eptifiba... | Abciximab may lead to a major life threatening interaction when taken with Eptifibatide and Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Tolmetin and Tolmetin may cause ... |
DB01168 | DB04896 | 1,053 | 901 | [
"DDInter1526",
"DDInter1220"
] | Procarbazine | Milnacipran | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment of depression [F3928, F3934, A175786, A175951]. Furthermore, in 2009 the US FDA approved milnacipran for the a... | Major | 2 | [
[
[
1053,
25,
901
]
],
[
[
1053,
25,
41
],
[
41,
1,
901
]
],
[
[
1053,
64,
1349
],
[
1349,
40,
901
]
],
[
[
1053,
21,
28722
],
[
28722,
... | [
[
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Milnacipran"
]
],
[
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levomilnacipran"
],
[
"Levomilnacipran... | Procarbazine may lead to a major life threatening interaction when taken with Levomilnacipran and Levomilnacipran (Compound) resembles Milnacipran (Compound)
Procarbazine may lead to a major life threatening interaction when taken with Meperidine and Meperidine (Compound) resembles Milnacipran (Compound)
Procarbazine (... |
DB00393 | DB11767 | 854 | 1,583 | [
"DDInter1295",
"DDInter1643"
] | Nimodipine | Sarilumab | Nimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction ... | Sarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6. Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approve... | Moderate | 1 | [
[
[
854,
24,
1583
]
],
[
[
854,
1,
1081
],
[
1081,
24,
1583
]
],
[
[
854,
25,
384
],
[
384,
24,
1583
]
],
[
[
854,
63,
58
],
[
58,
2... | [
[
[
"Nimodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarilumab"
]
],
[
[
"Nimodipine",
"{u} (Compound) resembles {v} (Compound)",
"Nicardipine"
],
[
"Nicardipine",
"{u} may cause a modera... | Nimodipine (Compound) resembles Nicardipine (Compound) and Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab
Nimodipine may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate di... |
DB01181 | DB08826 | 1,532 | 1,292 | [
"DDInter906",
"DDInter489"
] | Ifosfamide | Deferiprone | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA ap... | Major | 2 | [
[
[
1532,
25,
1292
]
],
[
[
1532,
21,
28759
],
[
28759,
60,
1292
]
],
[
[
1532,
24,
1017
],
[
1017,
63,
1292
]
],
[
[
1532,
63,
482
],
[
4... | [
[
[
"Ifosfamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
]
],
[
[
"Ifosfamide",
"{u} (Compound) causes {v} (Side Effect)",
"Connective tissue disorder"
],
[
"Connective tissue disorder",
"{u} (... | Ifosfamide (Compound) causes Connective tissue disorder (Side Effect) and Connective tissue disorder (Side Effect) is caused by Deferiprone (Compound)
Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerba... |
DB00687 | DB14783 | 870 | 287 | [
"DDInter747",
"DDInter574"
] | Fludrocortisone | Diroximel fumarate | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting ... | Moderate | 1 | [
[
[
870,
24,
287
]
],
[
[
870,
63,
1101
],
[
1101,
24,
287
]
],
[
[
870,
24,
384
],
[
384,
24,
287
]
],
[
[
870,
1,
1220
],
[
1220,
... | [
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexaroten... | Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Ide... |
DB00855 | DB01067 | 213 | 959 | [
"DDInter72",
"DDInter826"
] | Aminolevulinic acid | Glipizide | A compound produced from succinyl-CoA and glycine as an intermediate in heme synthesis. It is used as a photochemotherapy for actinic keratosis. [PubChem] | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Major | 2 | [
[
[
213,
25,
959
]
],
[
[
213,
64,
245
],
[
245,
40,
959
]
],
[
[
213,
25,
1411
],
[
1411,
1,
959
]
],
[
[
213,
21,
28987
],
[
28987,
... | [
[
[
"Aminolevulinic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glipizide"
]
],
[
[
"Aminolevulinic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glimepiride"
],
[
"Glimepi... | Aminolevulinic acid may lead to a major life threatening interaction when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)
Aminolevulinic acid may lead to a major life threatening interaction when taken with Tolbutamide and Tolbutamide (Compound) resembles Glipizide (Compound)
Aminolevul... |
DB08870 | DB14730 | 850 | 1,412 | [
"DDInter228",
"DDInter264"
] | Brentuximab vedotin | Calaspargase pegol | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Asparaginase is an important agent used to treat acute lymphoblastic leukemia (ALL) . Asparagine is incorporated into most proteins, and the synthesis of proteins is stopped when asparagine is absent, which inhibits RNA and DNA synthesis, resulting in a halt in cellular proliferation. This forms the basis of asparagina... | Moderate | 1 | [
[
[
850,
24,
1412
]
],
[
[
850,
24,
250
],
[
250,
24,
1412
]
],
[
[
850,
63,
1439
],
[
1439,
24,
1412
]
],
[
[
850,
64,
581
],
[
581,
... | [
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"B... | Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab and Blinatumomab may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when ta... |
DB00717 | DB06674 | 1,197 | 908 | [
"DDInter1312",
"DDInter837"
] | Norethisterone | Golimumab | Norethisterone, also known as norethindrone, is a synthetic progestational hormone belonging to the 19-nortestosterone-derived class of progestins. It is further classified as a second-generation progestin, along with [levonorgestrel] and its derivatives, and is the active form of several other progestins including [no... | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Moderate | 1 | [
[
[
1197,
24,
908
]
],
[
[
1197,
23,
14
],
[
14,
24,
908
]
],
[
[
1197,
1,
873
],
[
873,
24,
908
]
],
[
[
1197,
63,
1031
],
[
1031,
... | [
[
[
"Norethisterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Golimumab"
]
],
[
[
"Norethisterone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rosuvastatin"
],
... | Norethisterone may cause a minor interaction that can limit clinical effects when taken with Rosuvastatin and Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Norethisterone (Compound) resembles Norgestimate (Compound) and Norgestimate may cause a moderate interacti... |
DB05294 | DB12161 | 1,069 | 730 | [
"DDInter1917",
"DDInter512"
] | Vandetanib | Deutetrabenazine | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Deutetrabenazine is a novel, highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the management of chorea associated with Huntington’s disease. It is a hexahydro-dimethoxybenzoquinolizine derivative and a deuterated . The presence of deuterium in deutetrabenazine increases the half-lives ... | Major | 2 | [
[
[
1069,
25,
730
]
],
[
[
1069,
62,
112
],
[
112,
23,
730
]
],
[
[
1069,
64,
322
],
[
322,
24,
730
]
],
[
[
1069,
63,
1559
],
[
1559,
... | [
[
[
"Vandetanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Vandetanib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Met... | Vandetanib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Deutetrabenazine
Vandetanib may lead to a major life threatening interaction when taken with Epirubicin and Epirubicin ma... |
DB01268 | DB11095 | 1,151 | 235 | [
"DDInter1731",
"DDInter505"
] | Sunitinib | Desirudin | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Desirudin is a direct inhibitor of human thrombin. It has a protein structure that is similar to that of hirudin, the naturally occurring anticoagulant present in the peripharyngeal glands in the medicinal leech, Hirudo medicinalis. Hirudin is a single polypeptide chain of 65 amino acids residues and contains three dis... | Moderate | 1 | [
[
[
1151,
24,
235
]
],
[
[
1151,
63,
1100
],
[
1100,
24,
235
]
],
[
[
1151,
64,
1230
],
[
1230,
24,
235
]
],
[
[
1151,
24,
1409
],
[
1409,... | [
[
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desirudin"
]
],
[
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venlafaxine"
],
[
... | Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Desirudin
Sunitinib may lead to a major life threatening interaction when taken with Citalopram and Citalopram may cause a... |
DB00835 | DB01105 | 100 | 222 | [
"DDInter245",
"DDInter1665"
] | Brompheniramine | Sibutramine | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Moderate | 1 | [
[
[
100,
24,
222
]
],
[
[
100,
6,
8374
],
[
8374,
45,
222
]
],
[
[
100,
63,
1563
],
[
1563,
24,
222
]
],
[
[
100,
24,
1617
],
[
1617,
... | [
[
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Brompheniramine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (... | Brompheniramine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sibutramine (Compound)
Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Halazepam and Halazepam may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine
Bromphen... |
DB01128 | DB12301 | 918 | 907 | [
"DDInter204",
"DDInter585"
] | Bicalutamide | Doravirine | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Doravirine is an HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) intended to be administered in combination with other antiretroviral medicines.[L12729,L4562] Doravirine is available by itself or as a combination product of doravirine (100 mg), lamivudine (300 mg), and tenofovir disoproxil fumarate (300 mg... | Minor | 0 | [
[
[
918,
23,
907
]
],
[
[
918,
24,
1478
],
[
1478,
23,
907
]
],
[
[
918,
24,
159
],
[
159,
62,
907
]
],
[
[
918,
63,
600
],
[
600,
2... | [
[
[
"Bicalutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doravirine"
]
],
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
... | Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a minor interaction that can limit clinical effects when taken with Doravirine
Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Lar... |
DB00827 | DB00959 | 646 | 1,486 | [
"DDInter383",
"DDInter1191"
] | Cinoxacin | Methylprednisolone | Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections. | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Major | 2 | [
[
[
646,
25,
1486
]
],
[
[
646,
64,
175
],
[
175,
40,
1486
]
],
[
[
646,
64,
167
],
[
167,
1,
1486
]
],
[
[
646,
25,
1220
],
[
1220,
... | [
[
[
"Cinoxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Cinoxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triamcinolone"
],
[
"Triamcinolone",
... | Cinoxacin may lead to a major life threatening interaction when taken with Triamcinolone and Triamcinolone (Compound) resembles Methylprednisolone (Compound)
Cinoxacin may lead to a major life threatening interaction when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Methylprednisolone (Compound)
Ci... |
DB00344 | DB01233 | 1,302 | 1,311 | [
"DDInter1543",
"DDInter1197"
] | Protriptyline | Metoclopramide | Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may ... | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Moderate | 1 | [
[
[
1302,
24,
1311
]
],
[
[
1302,
24,
1151
],
[
1151,
40,
1311
]
],
[
[
1302,
25,
1425
],
[
1425,
40,
1311
]
],
[
[
1302,
6,
12523
],
[
12... | [
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
]
],
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
],... | Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Sunitinib (Compound) resembles Metoclopramide (Compound)
Protriptyline may lead to a major life threatening interaction when taken with Cisapride and Cisapride (Compound) resembles Metoclopramide (Compound)
Protr... |
DB01263 | DB08899 | 859 | 129 | [
"DDInter1494",
"DDInter649"
] | Posaconazole | Enzalutamide | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
859,
24,
129
]
],
[
[
859,
63,
918
],
[
918,
1,
129
]
],
[
[
859,
6,
8374
],
[
8374,
45,
129
]
],
[
[
859,
21,
29377
],
[
29377,
... | [
[
[
"Posaconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Posaconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
],
... | Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Posaconazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Posaconazole (Compound) causes Musculoskeletal pain (S... |
DB00963 | DB09135 | 1,263 | 1,211 | [
"DDInter241",
"DDInter967"
] | Bromfenac | Ioxilan | Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Ophthalmic NSAIDs are becoming a cornerstone for the management of ocular pain and inflammation. Their well-characterized anti-inflammatory activity, analgesic property, and established safety record have also made NSAIDs an important tool f... | Ioxilan is a tri-iodinated diagnostic contrast agent. Intravascular injection results in opacification of vessels in the path of flow of the contrast medium, permitting radiographic visualization of the internal structures of the human body until significant hemodilution occurs. | Major | 2 | [
[
[
1263,
25,
1211
]
],
[
[
1263,
24,
712
],
[
712,
25,
1211
]
],
[
[
1263,
63,
1512
],
[
1512,
25,
1211
]
],
[
[
1263,
1,
831
],
[
831,
... | [
[
[
"Bromfenac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ioxilan"
]
],
[
[
"Bromfenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olsalazine"
],
[
"Olsalazine",
... | Bromfenac may cause a moderate interaction that could exacerbate diseases when taken with Olsalazine and Olsalazine may lead to a major life threatening interaction when taken with Ioxilan
Bromfenac may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may lead to a m... |
DB00622 | DB01050 | 1,081 | 848 | [
"DDInter1287",
"DDInter900"
] | Nicardipine | Ibuprofen | A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. [Pub... | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally p... | Moderate | 1 | [
[
[
1081,
24,
848
]
],
[
[
1081,
24,
1053
],
[
1053,
1,
848
]
],
[
[
1081,
6,
3486
],
[
3486,
45,
848
]
],
[
[
1081,
21,
28929
],
[
28929,... | [
[
[
"Nicardipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
]
],
[
[
"Nicardipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
],
[... | Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine (Compound) resembles Ibuprofen (Compound)
Nicardipine (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Ibuprofen (Compound)
Nicardipine (Compound) causes Confusional state (Side Effect) ... |
DB01044 | DB11901 | 246 | 913 | [
"DDInter809",
"DDInter107"
] | Gatifloxacin | Apalutamide | Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatiflox... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Major | 2 | [
[
[
246,
25,
913
]
],
[
[
246,
62,
112
],
[
112,
23,
913
]
],
[
[
246,
64,
600
],
[
600,
24,
913
]
],
[
[
246,
24,
28
],
[
28,
24,
... | [
[
[
"Gatifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
],
[
[
"Gatifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metr... | Gatifloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Gatifloxacin may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole m... |
DB08931 | DB14568 | 947 | 982 | [
"DDInter1600",
"DDInter1000"
] | Riociguat | Ivosidenib | Riociguat is a soluble guanylate cyclase (sGC) agonist approved in the USA, Europe and several other regions for patients with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for the treatment of patients with inoperable CTEPH (chronic thromboembolic pulmonary hypertension), or persistent/recurre... | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Moderate | 1 | [
[
[
947,
24,
982
]
],
[
[
947,
63,
1101
],
[
1101,
23,
982
]
],
[
[
947,
63,
1478
],
[
1478,
24,
982
]
],
[
[
947,
24,
286
],
[
286,
... | [
[
[
"Riociguat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Riociguat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Riociguat may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Riociguat may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor m... |
DB00615 | DB06605 | 690 | 1,409 | [
"DDInter1589",
"DDInter108"
] | Rifabutin | Apixaban | A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients. | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Moderate | 1 | [
[
[
690,
24,
1409
]
],
[
[
690,
6,
7950
],
[
7950,
45,
1409
]
],
[
[
690,
21,
28787
],
[
28787,
60,
1409
]
],
[
[
690,
25,
1670
],
[
1670,... | [
[
[
"Rifabutin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
]
],
[
[
"Rifabutin",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
... | Rifabutin (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Apixaban (Compound)
Rifabutin (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Apixaban (Compound)
Rifabutin may lead to a major life threatening interaction when taken with Eliglustat and Eliglustat may cause a m... |
DB00612 | DB01088 | 1,121 | 714 | [
"DDInter216",
"DDInter908"
] | Bisoprolol | Iloprost | Bisoprolol is a cardioselective β1-adrenergic blocking agent used to treat high blood pressure.[A180472,L7219] It is considered a potent drug with a long-half life that can be used once daily to reduce the need for multiple doses of antihypertensive drugs. Bisoprolol is generally well tolerated, likely due to its β1-ad... | Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties. | Moderate | 1 | [
[
[
1121,
24,
714
]
],
[
[
1121,
23,
1479
],
[
1479,
24,
714
]
],
[
[
1121,
63,
1648
],
[
1648,
24,
714
]
],
[
[
1121,
24,
1445
],
[
1445,... | [
[
[
"Bisoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
]
],
[
[
"Bisoprolol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Acetylsalicylic acid"
],
... | Bisoprolol may cause a minor interaction that can limit clinical effects when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Iloprost
Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with Aldes... |
DB00238 | DB00307 | 188 | 1,101 | [
"DDInter1285",
"DDInter202"
] | Nevirapine | Bexarotene | A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class. | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Minor | 0 | [
[
[
188,
23,
1101
]
],
[
[
188,
6,
8374
],
[
8374,
45,
1101
]
],
[
[
188,
21,
28762
],
[
28762,
60,
1101
]
],
[
[
188,
23,
608
],
[
608,
... | [
[
[
"Nevirapine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
]
],
[
[
"Nevirapine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Nevirapine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bexarotene (Compound)
Nevirapine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Bexarotene (Compound)
Nevirapine may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine... |
DB00814 | DB08895 | 1,171 | 976 | [
"DDInter1143",
"DDInter1825"
] | Meloxicam | Tofacitinib | Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and rheumatoid arthritis. With a longer half-life than most other NSAIDS, it is a favorable option for those who require once-daily dosing. Meloxicam is ... | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Moderate | 1 | [
[
[
1171,
24,
976
]
],
[
[
1171,
24,
214
],
[
214,
63,
976
]
],
[
[
1171,
63,
723
],
[
723,
24,
976
]
],
[
[
1171,
1,
1027
],
[
1027,
... | [
[
[
"Meloxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Meloxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
... | Meloxicam may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Meloxicam may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Apr... |
DB00261 | DB00867 | 702 | 1,052 | [
"DDInter93",
"DDInter1606"
] | Anagrelide | Ritodrine | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Adrenergic beta-agonist used to control premature labor. | Major | 2 | [
[
[
702,
25,
1052
]
],
[
[
702,
18,
4884
],
[
4884,
57,
1052
]
],
[
[
702,
25,
1148
],
[
1148,
63,
1052
]
],
[
[
702,
24,
1559
],
[
1559,
... | [
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ritodrine"
]
],
[
[
"Anagrelide",
"{u} (Compound) downregulates {v} (Gene)",
"POLR2I"
],
[
"POLR2I",
"{u} (Gene) is downregulated by {v} (Compound)",... | Anagrelide (Compound) downregulates POLR2I (Gene) and POLR2I (Gene) is downregulated by Ritodrine (Compound)
Anagrelide may lead to a major life threatening interaction when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Ritodrine
Anagrelide may ... |
DB00678 | DB01097 | 240 | 1,377 | [
"DDInter1095",
"DDInter1033"
] | Losartan | Leflunomide | Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough simila... | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Moderate | 1 | [
[
[
240,
24,
1377
]
],
[
[
240,
6,
6017
],
[
6017,
45,
1377
]
],
[
[
240,
21,
28864
],
[
28864,
60,
1377
]
],
[
[
240,
24,
1144
],
[
1144,... | [
[
[
"Losartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Leflunomide"
]
],
[
[
"Losartan",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
... | Losartan (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Leflunomide (Compound)
Losartan (Compound) causes Erythema multiforme (Side Effect) and Erythema multiforme (Side Effect) is caused by Leflunomide (Compound)
Losartan may cause a moderate interaction that could exacerbate diseases when taken with Nat... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.